

FOR IMMEDIATE RELEASE

CONTACT:

**Ben Hendricks**

(617) 226-7183 office

(919) 522-2978 cell

[ben@thechtgroup.com](mailto:ben@thechtgroup.com)

**Alison Morris**

(617) 226-7186 office

(507) 261-7016 cell

[alison@thechtgroup.com](mailto:alison@thechtgroup.com)

## PRESENTATION AT ANNUAL MEETING PROMOTES THE USE OF SOLVD PREVENTION IN STAGE B HEART FAILURE PATIENTS

*Research Shows Stepwise Progression with SOLVD Prevention in Stage B Heart Failure  
Patients*

**SAN DIEGO (Sept. 14, 2010)** – The 14th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) will feature several talks and a discussion in a session entitled “Prevention of Heart Failure Progression: New Insights For Stage B Management” by Dr. Barry H. Greenberg, Cardiologist, and founding member of the Heart Failure Society of America. This session will focus on insights obtained from the SOLVD Prevention Trial which enrolled asymptomatic patients with evidence of LV dysfunction.

Dr. Greenberg’s discussion highlights the results of the SOLVD Prevention Trial including the main trial results and other important insights gained from SOLVD substudies and the SOLVD registry. The findings strongly support the concept of early recognition and treatment of the Stage B patient. Greenberg will emphasize that despite the persuasive argument for early diagnosis and treatment, the healthcare system has still not aggressively approached this issue, thereby missing an opportunity to prevent progression of heart failure.

“Many substudies of SOLVD show what is going on mechanistically in Stage B patients,” said Dr. Greenberg. “We need to translate the information that ACE inhibitors prevent progressive maladaptive changes in LV structure and function over time into strategies that focus on treating Stage B patients early and properly.”

Greenberg is a leader and developer of new techniques and drugs to treat heart failure. Since 1971, he has been working in cardiology as a Staff Associate at the National Institutes of Health in the Heart, Lung and Blood, Lipid Metabolism Branch. He previously served as Director of the Coronary Care Unit at Oregon Health Sciences University in Portland, Oregon. Dr. Greenberg is currently Professor of Medicine at UCSD School of Medicine and Director, Advanced Heart Failure Treatment Program at UCSD.

For a complete list of annual meeting sessions or for details on attending the conference, call (617) 226-7183 or visit [www.hfsa.org](http://www.hfsa.org) and click on Annual Scientific Meeting. There is no registration fee for accredited journalists. Interview areas will be available on-site in addition to a fully-staffed press room with phone and internet accessibility. You may follow news from the meeting on Twitter #HFSA.

###

### **About Heart Failure**

Heart failure is a progressive condition in which the heart muscle becomes weakened after it is injured, most commonly from heart attack or high blood pressure, and gradually loses its ability to pump enough blood to supply the body's needs. Many people are not aware they have heart failure because the symptoms are often mistaken for signs of getting older. Heart failure affects from 4.6 to 4.8 million individuals in the United States. Demographic and clinical evidence strongly suggests that the prevalence of heart failure will increase throughout the next decade. Ten to 15 years ago heart failure was considered a "death sentence;" however, recent advances in treatment have shown that early diagnosis and proper care in early stages of the condition are key to slowing, stopping or in some cases reversing progression, improving quality of life, and extending life expectancy. For more information on heart failure, please visit [www.abouthf.org](http://www.abouthf.org).

### **About the Heart Failure Society of America**

The Heart Failure Society of America (HFSA) is a nonprofit educational organization, founded in 1994 as the first organized association of heart failure experts. The HFSA provides a forum for all those interested in heart function, heart failure research and patient care. The Society also serves as a resource for governmental agencies (FDA, NIH, NHLBI, CMS). The HFSA Annual Scientific Meeting is designed to highlight recent advances in the development of strategies to address the complex epidemiological, clinical and therapeutic issues of heart failure. Additional information on HFSA can be found at [www.hfsa.org](http://www.hfsa.org).